Single- and double-stranded oligonucleotide therapeutics - Novartis
Latest Information Update: 17 Apr 2019
At a glance
- Originator Novartis
- Class Oligodeoxyribonucleotides; Oligoribonucleotides
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Undefined in USA
- 03 Aug 2012 Early research in Undefined indication in USA (unspecified route)